Liu Q, Chen H, Ojode T, et al. WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4. Blood. 2012;120(1):181–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al Ustwani O, Kurzrock R, Wetzler M. Genetics on a WHIM. Br J Haematol. 2014;164(1):15–23.

Article  CAS  PubMed  Google Scholar 

US National Center for Biotechnology Information. C-X-C motif chemokine receptor 4 [Homo sapiens (human)]. 2024. https://www.ncbi.nlm.nih.gov/gene/7852. Accessed 21 May 2024.

Giorgiutti S, Rottura J, Korganow AS, et al. CXCR4: from B-cell development to B cell-mediated diseases. Life Sci Alliance. 2024. https://doi.org/10.26508/lsa.202302465.

Article  PubMed  PubMed Central  Google Scholar 

US Food and Drug Administration. FDA approves first drug for WHIM syndrome, a rare disorder that can lead to recurrent, life-threatening infections [media release]. 30 Apr 2024. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-whim-syndrome-rare-disorder-can-lead-recurrent-life-threatening-infections.

Roselli G, Martini E, Lougaris V, et al. CXCL12 mediates aberrant costimulation of B lymphocytes in warts, hypogammaglobulinemia, infections, myelokathexis immunodeficiency. Front Immunol. 2017;8:1068.

Article  PubMed  PubMed Central  Google Scholar 

Heusinkveld LE, Majumdar S, Gao JL, et al. WHIM syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39(6):532–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geier CB, Ellison M, Cruz R, et al. Disease progression of WHIM syndrome in an international cohort of 66 pediatric and adult patients. J Clin Immunol. 2022;42(8):1748–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balabanian K, Lagane B, Pablos JL, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood. 2005;105(6):2449–57.

Article  CAS  PubMed  Google Scholar 

X4 Pharmaceuticals Inc. XOLREMDI™ (mavorixafor) capsules, for oral use: US prescribing information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218709s000lbl.pdf. Accessed 2 May 2024.

Mosi RM, Anastassova V, Cox J, et al. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. Biochem Pharmacol. 2012;83(4):472–9.

Article  CAS  PubMed  Google Scholar 

X4 Pharmaceuticals. X4 Pharmaceuticals announces FDA approval of XOLREMDITM (mavorixafor) capsules, first drug indicated in patients with WHIM syndrome [media release]. 29 Apr 2024. https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-fda-approval-xolremditm-mavorixafor.

X4 Pharmaceuticals. Science & pipeline. 2024. https://www.x4pharma.com/pipeline/. Accessed 22 May 2024.

United States Securities and Exchange Commission. FORM 10-K: annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2020. 2020. https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000162828021005202/xfor-20201231.htm. Accessed 16 May 2024.

X4 Pharmaceuticals. X4 Pharmaceuticals and Abbisko Therapeutics enter into oncology development and commercialization agreement for mavorixafor in Greater China [media release]. 17 Jul 2019. https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-and-abbisko-therapeutics-enter-oncology.

Shen D, Zhu L, Liu Y, et al. Efficacy evaluation and mechanism study on inhibition of breast cancer cell growth by multimodal targeted nanobubbles carrying AMD070 and ICG. Nanotechnology. 2020;31(24): 245102.

Article  CAS  PubMed  Google Scholar 

Stone ND, Dunaway SB, Flexner C, et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother. 2007;51(7):2351–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Badolato R, Alsina L, Azar A, et al. Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome. Blood. 2024. https://doi.org/10.1182/blood.2023022658.

Article  PubMed  Google Scholar 

X4 Pharmaceuticals. X4 Pharmaceuticals announces positive top-line results from 4WHIM global, pivotal phase 3 trial of once-daily, oral mavorixafor in WHIM syndrome [media release]. 29 Nov 2022. https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-positive-top-line-results-4whim.

Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136(26):2994–3003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Warren J, Walkovich K, Bolyard AA, et al. A phase 1b, open-label study of mavorixafor in patients with chronic neutropenic disorders [abstract no 308]. Pediatr Blood Cancer. 2023;70(S3):S128–9.

Google Scholar 

US National Institutes of Health. ClinicalTrials.gov identifier NCT04154488. 2024. https://www.clinicaltrials.gov/study/NCT04154488. Accessed 11 Jun 2024.

Article  Google Scholar 

Warren JT, Dickerson KE, Sharathkumar AA, et al. Mavorixafor for patients with chronic neutropenic disorders treated with G-CSF: preliminary response data and G-CSF dose reduction in an ongoing phase 2, open-label, multicenter study support reduction in G-CSF dosing. Blood. 2023;142(Suppl 1):1160-1.